Table 1.

The antitumor activities of the target compounds against cancerous A-549, HepG-2, MCF-7, HCT-116 and normal RPE-1 cell lines expressed as IC₅₀ values.

Compd. No	IC50 (mean ± SD) (µM)
	A-549	HepG-2	MCF-7	HCT-116	RPE-1
3	–	57.56 ± 12.23	–	–	–
4	30.91 ± 0.65	12.53 ± 0.51	19.57 ± 1.10	20.30 ± 0.33	78.27 ± 1.56
7	20.45 ± 0.28	10.45 ± 0.13	20.31 ± 0.66	32.05 ± 0.42	82.58 ± 0.52
8	–	47.02 ± 0.51	46.49 ± 0.42	–	–
9	19.81 ± 0.65	8.39 ± 0.20	21.15 ± 2.45	23.60 ± 0.22	87.22 ± 0.73
11	–	16.90 ± 0.09	–	–	–
12	–	36.44 ± 0.12	–	–	–
13	–	30.01 ± 0.06	30.83 ± 0.20	53.07 ± 0.69	–
Doxorubicin	–	13.76 ± 0.45	17.44 ± 0.46		–
Sunitinib	10.14 ± 0.50			9.67 ± 0.22

IC₅₀ Compound concentration required to inhibit growth by 50%, SD Standard deviation, each value is the mean of three values, (–) not detected.